Trial Profile
Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Levonorgestrel (Primary)
- Indications Adenocarcinoma; Atypical endometrial hyperplasia; Endometrial cancer
- Focus Therapeutic Use
- Acronyms LEVER
- 11 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 25 Sep 2019 Planned End Date changed from 30 Sep 2027 to 30 Sep 2026.
- 13 Jun 2019 Planned End Date changed from 30 Sep 2026 to 30 Sep 2027.